NCT06594874 2024-09-19A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid TumorsJiangsu Hansoh Pharmaceutical Co., Ltd.Phase 1 Not yet recruiting350 enrolled